メニュー
Request a Quote
お問い合わせ
JP
Whitepaper

Accelerating immuno-oncology therapeutic development: choosing the best preclinical model

preclinicalmodel512

Oncology research remains a major focal point of the pharmaceutical and biopharmaceutical industry. Standalone historic approaches such as chemotherapy, albeit effective, pose potential tolerability issues that often coincide with unintended systemic side effects.

Current approaches to oncology treatment often involve a multi-faceted therapeutic approach. Researchers strive to incorporate various drug types with the intent of combating cancer on multiple fronts with the goal of remission and elimination. The delicate interplay between homeostatic control mechanisms and cancer cells offers evolving opportunities for both therapeutic targeting and the development of new drug candidates.

Read this whitepaper to learn how Dr. Seyoum Ayehunie selects the most appropriate preclinical model.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Accelerating immuno-oncology therapeutic development: choosing the best preclinical model

Download Whitepaper